Get the Daily Brief
Latest Biotech News
Watchmaker licenses Caribou’s CRISPR‑Cas9 to solve NGS bottlenecks
Watchmaker Genomics secured a non‑exclusive license to foundational CRISPR‑Cas9 intellectual property from Caribou Biosciences to use the nuclease as a programmable binding tool for...
Sweden’s CubaseBio launches with €5.9M to map 3D transcriptomes
CubaseBio, a Stockholm startup, closed €5.9 million to commercialize a 3D spatial transcriptomics platform for organoids and intact tissues. Funding includes a €2M non‑dilutive EIC Transition...
Fujifilm opens UK mega‑CDMO: 19,000 L single‑use capacity comes online
Fujifilm Biotechnologies inaugurated its expanded Teesside site in the U.K., unveiling what it calls the largest single‑use CDMO facility in the country. The £400 million investment adds 2,000 L...
Gilead pays upfront for China’s Genhouse MAT2A asset – $1.5B deal on the table
Gilead Sciences struck a licensing deal with Genhouse Bio for GH31, a MAT2A‑targeting synthetic‑lethal oncology candidate, paying $80 million up front and agreeing up to $1.45 billion in...
FDA clears IND for CSPC’s SYH‑2082: new GLP‑1/GIP candidate enters US trials
CSPC Pharmaceutical Group received FDA clearance for an investigational new drug application for SYH‑2082, a long‑acting GLP‑1/GIP dual‑biased agonist intended for weight management in people with...
NeoGenomics posts 11% Q4 growth; NGS sales accelerate and salesforce to expand
NeoGenomics reported fourth‑quarter revenue of $190.2 million, up 11% year‑over‑year and topping consensus, driven by a shift to higher‑value testing and strong clinical revenue growth. The...
Compass posts second Phase‑3 win — Approval push begins
Compass Pathways reported positive results from two Phase 3 trials of its psilocybin therapy COMP360, and the company is preparing regulatory discussions aimed at seeking approval. The firm...
Ocular’s Axpaxli edges Eylea — Durability data sparks debate
Ocular Therapeutix disclosed Phase 3 results showing its investigational drug Axpaxli maintained vision with fewer injections versus a low-dose Eylea comparator, meeting the trial’s primary...
FDA rejects Disc’s bitopertin — Agency wants clinical endpoints
The FDA issued a complete response letter rejecting approval of Disc Medicine’s bitopertin for erythropoietic protoporphyria (EPP), citing uncertainty that the surrogate biomarker (percent change...
Gilead pays $80m upfront for China’s synthetic‑lethality asset — $1.45bn upside
Gilead signed a global deal for Genhouse Bio’s MAT2A‑targeting synthetic‑lethality asset GH31, paying $80 million upfront and structuring up to $1.45 billion in milestones plus tiered double‑digit...
Fujifilm opens UK mega‑CDMO — 19,000 L capacity online H1 2026
Fujifilm Biotechnologies inaugurated its expanded Teesside campus, unveiling the UK’s largest single‑use CDMO facility and a Bioprocess Innovation Centre. The £400 million investment adds 2,000 L...
Prima Mente deploys AI epigenome test for early Alzheimer’s — 89–97% detection reported
AI biology company Prima Mente unveiled Pleiades, an AI model that analyses DNA methylation patterns in cell‑free DNA to detect early‑stage Alzheimer’s and Parkinson’s from blood. The company...
Boehringer halts inhaled CF gene therapy program — Early trials terminated
Boehringer Ingelheim discontinued development of an inhaled gene therapy for cystic fibrosis that had entered early‑stage clinical testing, the company told Endpoints News. The sponsor decided to...
Former FDA oncology chief Pazdur says he was pressured on trial cuts — Agency turmoil
Richard Pazdur, who left the FDA’s top drug review role, told The Wall Street Journal he was asked to endorse agency messaging on reducing clinical‑trial requirements, saying he was handed a press...
European VCs form ELSC to unblock life‑sciences funding — €24bn in assets behind push
Major European venture firms launched the European Life Science Coalition (ELSC) with backing from Invest Europe and members managing over €24 billion to address structural underinvestment in...
Cell‑type gene regulatory map for Alzheimer’s — SIGNET reveals causal hubs
Researchers at UC Irvine developed SIGNET, a machine‑learning framework to infer causal gene regulatory networks at cell‑type resolution and applied it to Alzheimer’s disease. The team identified...
Pazdur: I was asked to cosign FDA trial cuts
Richard Pazdur told reporters he was pressured to endorse the FDA’s decision to reduce clinical trial requirements for new drug approvals. Pazdur, the former head of the agency’s oncology unit,...
Prasad under fire — staff complaints and Moderna rift
Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research, is facing internal complaints and public scrutiny tied to his handling of Moderna’s influenza vaccine submission....
FDA rejects Disc’s bitopertin — questions over biomarker
The FDA declined to approve Disc Medicine’s bitopertin for erythropoietic protoporphyria (EPP), citing doubts that the drug’s reduction in PPIX (a surrogate biomarker) reliably predicts clinical...
Gilead pays up for China’s Genhouse — $1.5B deal
Gilead acquired global rights to Genhouse Bio’s MAT2A-targeting cancer candidate (GH31), paying $80 million upfront and up to $1.45 billion in milestones. Genhouse has secured IND clearance in...